Ankur Drugs & Pharma Ltd. has informed BSE that it has received letter from Central Bank of India informing about the resignation of Mr. Anil Kumar Khadke as Nominee of Central Bank of India. Thus, Mr. Anil Kumar Khadke stands withdrawn as Nominee Director of the company effective March 15, 2013. The aforesaid letter will be placed in the forthcoming Board meeting of the company for approval of Board of Directors and to complete further formalities.

Ankur Drugs & Pharma Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2012. For the quarter, the company reported net sales of INR 315.707 million against INR 354.621 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 180.188 million against INR 225.435 million a year ago. Loss from ordinary activities before tax and net loss from ordinary activities after tax was INR 408.415 million or INR 21.12 per basic and diluted share against INR 366.246 million or INR 18.94 per basic and diluted share a year ago. For the nine months, the company reported net sales of INR 901.086 million against INR 1,076.937 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 548.364 million against INR 660.792 million a year ago. Loss from ordinary activities before tax and net profit from ordinary activities after tax was INR 1,278.020 million or INR 66.08 per basic and diluted share against INR 1,020.250 million or INR 52.75 per basic and diluted share a year ago.

Ankur Drugs & Pharma Ltd. announced that they will report Q3, 2013 results on Feb 14, 2013